Lavipharm (FRA:BXA0) Tariff Resilience Score: 0/10 (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BXA0 Lavipharm SA FRA:BXA0
79 GF Score
Price €1.55
GF Value €1.03
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lavipharm Tariff Resilience Score?

Lavipharm has the Tariff Resilience Score of 0, which implies that the company might have .

Lavipharm has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Lavipharm might have .

Lavipharm  (FRA:BXA0) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Lavipharm Tariff Resilience Score Related Terms

FRA:BXA0
79GF Score
Lavipharm SA FRA:BXA0
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lavipharm (FRA:BXA0) Overvalued in 2026?

Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued. The current stock price of €1.55 is trading 50.5% above its estimated GF Value™ of €1.03. GuruFocus considers Lavipharm to be Significantly Overvalued.

Key valuation signals for FRA:BXA0:

  • Tariff Resilience Score: 0
  • GF Value™: €1.03 vs. price of €1.55 (50.5% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the FRA:BXA0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lavipharm Business Description

Other Exchanges LAVI:Greece
Address 12, Agias Marinas Street, PO Box 59, Paiania, GRC, 19002
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
79GF Score

Get the complete analysis for FRA:BXA0

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€1.03
GF Value